Novartis: EU approval for Jakavi® for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea

Jakavi® (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea PV is a rare blood cancer associated with an overproduction of blood cells that can lead to serious cardiovascular complications … Read the full press release →